J&J’s Gorsky Promises Prioritization Of OTC Business
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson’s Q2 was another quarter of flat consumer products growth, with the return of some OTCs to market delayed until 2013. In his quarterly earnings call debut, CEO Alex Gorsky emphasized the firm’s commitment to diversification and restoring the supply of OTC products.
You may also be interested in...
Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.
McNeil Remediation Stretches Out, Dragging On J&J Consumer Sales
The latest delay in Johnson & Johnson’s remediation of its McNeil OTC manufacturing pushes back FDA’s review of the Fort Washington, Pa., facility to “late 2013.” The firm’s Q1 results saw the worldwide consumer business fall 2.4% to $3.60 billion, including negative currency exchange effects.
J&J CEO Choice Likely Will Not Raise Consumer Business Profile
Alex Gorsky will replace William Weldon as Johnson & Johnson CEO in April. Like his predecessor, who has led during a time of extensive OTC recalls, Gorsky’s experience with J&J comprises management of Rx pharmaceutical and medical device businesses, with no consumer background.